Patient Counselling Resources

Patient counselling is paramount when looking at patient compliance and adherence to medication.

We have created some useful resources to support your consultations. These materials provide guidance to healthcare professionals when transitioning an eligible patient with non-valvular atrial fibrillation from warfarin to Xarelto for stroke prevention, as well as explaining to a patient why they are being transitioned.

Prescribers counselling checklist for (SPAF) patients initiated on Xarelto

This checklist is a practical guide to support your anticoagulation consultation.

Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto

This checklist includes practical considerations for consultation with your patients with NVAF being initiated on Xarelto, addressing key FAQs into the conversation.

Prescribers counselling checklist for patients with DVT / PE initiated or transitioned to Xarelto

This checklist is a practical guide to support your anticoagulation consultation.

Patient transition booklet for non-valvular atrial fibrillation

A simple FAQ booklet which can be emailed to the patient / carer following consultation. Further support resources are available for AF patients who’ve been prescribed Xarelto here.

Patient transition booklet for venous thromboembolism

A simple FAQ booklet which can be emailed to the patient / carer following consultation. Further support resources are available for VTE patients who’ve been prescribed Xarelto here.

We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Reporting adverse events and quality complaints

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: pvuk@bayer.com

Further information is available on the "contact" tab at www.bayer.co.uk.